Phenex, J&J deal

Phenex and Johnson & Johnson's Janssen Biotech Inc. subsidiary partnered to discover compounds against RAR-related orphan receptor C thymus-specific isoform ( RORgamma2; RORgammaT) to treat chronic autoimmune and inflammatory disorders, including rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). The partners will optimize products for preclinical development, after which Janssen will be responsible for continued development and worldwide commercialization of any compounds developed under the deal. ...